BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, Chaisson RE, Williams BG, Harries AD, Granich RM. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012;9:e1001270. [PMID: 22911011 DOI: 10.1371/journal.pmed.1001270] [Cited by in Crossref: 221] [Cited by in F6Publishing: 206] [Article Influence: 24.6] [Reference Citation Analysis]
Number Citing Articles
1 Rhines AS, Feldman MW, Bendavid E. Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting. AIDS 2018;32:2129-40. [PMID: 30096067 DOI: 10.1097/QAD.0000000000001959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gupta S, Granich R. When will sub-Saharan Africa adopt HIV treatment for all? South Afr J HIV Med 2016;17:459. [PMID: 29568615 DOI: 10.4102/sajhivmed.v17i1.459] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
3 Christinet V, Comte E, Ciaffi L, Odermatt P, Serafini M, Antierens A, Rossel L, Nomo AB, Nkemenang P, Tsoungui A, Delhumeau C, Calmy A. Impact of human immunodeficiency virus on the severity of buruli ulcer disease: results of a retrospective study in cameroon. Open Forum Infect Dis 2014;1:ofu021. [PMID: 25734094 DOI: 10.1093/ofid/ofu021] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
4 Harries AD, Ford N, Jahn A, Schouten EJ, Libamba E, Chimbwandira F, Maher D. Act local, think global: how the Malawi experience of scaling up antiretroviral treatment has informed global policy. BMC Public Health 2016;16:938. [PMID: 27600800 DOI: 10.1186/s12889-016-3620-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
5 Thacher EG, Cavassini M, Audran R, Thierry AC, Bollaerts A, Cohen J, Demoitié MA, Ejigu D, Mettens P, Moris P, Ofori-Anyinam O, Spertini F. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. AIDS 2014;28:1769-81. [PMID: 24911353 DOI: 10.1097/QAD.0000000000000343] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
6 Tomita A, Smith CM, Lessells RJ, Pym A, Grant AD, de Oliveira T, Tanser F. Space-time clustering of recently-diagnosed tuberculosis and impact of ART scale-up: Evidence from an HIV hyper-endemic rural South African population. Sci Rep 2019;9:10724. [PMID: 31341191 DOI: 10.1038/s41598-019-46455-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 McLaren ZM, Sharp A, Brouwer E, Nanoo A. The Impact of Anti-Retroviral Therapy on Tuberculosis Detection at the National Level in South Africa. Am J Trop Med Hyg 2018;99:1407-14. [PMID: 30277200 DOI: 10.4269/ajtmh.17-0530] [Reference Citation Analysis]
8 Harries AD, Lin Y, Kumar AMV, Satyanarayana S, Takarinda KC, Dlodlo RA, Zachariah R, Olliaro P. What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030? F1000Res 2018;7:F1000 Faculty Rev-1011. [PMID: 30026917 DOI: 10.12688/f1000research.14821.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
9 Meijerink H, Wisaksana R, Lestari M, Meilana I, Chaidir L, van der Ven AJ, Alisjahbana B, van Crevel R. Active and latent tuberculosis among HIV-positive injecting drug users in Indonesia. J Int AIDS Soc 2015;18:19317. [PMID: 25690530 DOI: 10.7448/IAS.18.1.19317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
10 Manabe YC, Worodria W, van Leth F, Mayanja-Kizza H, Traore AN, Ferro J, Pakker N, Frank M, Grobusch MP, Colebunders R, Cobelens F. Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial. Am J Trop Med Hyg 2016;95:1265-71. [PMID: 27928077 DOI: 10.4269/ajtmh.16-0239] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
11 Alba S, Rood E, Bakker MI, Straetemans M, Glaziou P, Sismanidis C. Development and validation of a predictive ecological model for TB prevalence. Int J Epidemiol 2018;47:1645-57. [PMID: 30124858 DOI: 10.1093/ije/dyy174] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Chakaya JM, Harries AD, Marks GB. Ending tuberculosis by 2030-Pipe dream or reality? Int J Infect Dis 2020;92S:S51-4. [PMID: 32114202 DOI: 10.1016/j.ijid.2020.02.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
13 Ngugi SK, Muiruri P, Odero T, Gachuno O. Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study. BMC Infect Dis 2020;20:294. [PMID: 32664847 DOI: 10.1186/s12879-020-05011-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Jockers D, Langlotz S, French D, Bärnighausen T. HIV treatment and worker absenteeism: Quasi-experimental evidence from a large-scale health program in South Africa. J Health Econ 2021;79:102479. [PMID: 34438129 DOI: 10.1016/j.jhealeco.2021.102479] [Reference Citation Analysis]
15 De Cock KM, El-Sadr WM. Clinical trials provide the evidence critical for patient empowerment. J Int AIDS Soc 2013;16:18811. [PMID: 23962587 DOI: 10.7448/IAS.16.1.18811] [Reference Citation Analysis]
16 Maniewski U, Payen MC, Delforge M, De Wit S. Is systematic screening and treatment for latent tuberculosis infection in HIV patients useful in a low endemic setting? Acta Clin Belg 2017;72:238-41. [PMID: 27686180 DOI: 10.1080/17843286.2016.1237696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Kumar AM, Gupta D, Gupta RS, Satyanarayana S, Wilson N, Zachariah R, Lawn SD, Harries AD. HIV testing in people with presumptive tuberculosis: time for implementation. Lancet Respir Med 2013;1:7-9. [PMID: 24321791 DOI: 10.1016/S2213-2600(12)70050-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
18 Granich R, Gupta S. 90-90-90 HIV targets: implications for HIV-associated tuberculosis. Curr Opin HIV AIDS 2018;13:528-37. [PMID: 30188404 DOI: 10.1097/COH.0000000000000498] [Reference Citation Analysis]
19 Chindelevitch L, Menzies NA, Pretorius C, Stover J, Salomon JA, Cohen T. Evaluating the potential impact of enhancing HIV treatment and tuberculosis control programmes on the burden of tuberculosis. J R Soc Interface 2015;12:20150146. [PMID: 25878131 DOI: 10.1098/rsif.2015.0146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
20 Giovannoni G, Lang S, Wolff R, Duffy S, Hyde R, Kinter E, Wakeford C, Sormani MP, Kleijnen J. A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis. Neurol Ther 2020;9:359-74. [PMID: 32989721 DOI: 10.1007/s40120-020-00212-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Cresswell FV, Meya DB, Kagimu E, Grint D, Te Brake L, Kasibante J, Martyn E, Rutakingirwa M, Quinn CM, Okirwoth M, Tugume L, Ssembambulidde K, Musubire AK, Bangdiwala AS, Buzibye A, Muzoora C, Svensson EM, Aarnoutse R, Elliott AM, Boulware DR. High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly HIV-positive Ugandan adults: a phase II open-label randomised controlled trial. Clin Infect Dis 2021:ciab162. [PMID: 33693537 DOI: 10.1093/cid/ciab162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 North CM, MacNaughton P, Lai PS, Vallarino J, Okello S, Kakuhikire B, Tsai AC, Castro MC, Siedner MJ, Allen JG, Christiani DC. Personal carbon monoxide exposure, respiratory symptoms, and the potentially modifying roles of sex and HIV infection in rural Uganda: a cohort study. Environ Health 2019;18:73. [PMID: 31429759 DOI: 10.1186/s12940-019-0517-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
23 Collins S, Geffen N. Community views: balancing the public health benefits of earlier antiretroviral treatment with the implications for individual patients - perspectives from the community. Curr Opin HIV AIDS 2014;9:4-10. [PMID: 24247668 DOI: 10.1097/COH.0000000000000024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Meintjes G, Brust JCM, Nuttall J, Maartens G. Management of active tuberculosis in adults with HIV. Lancet HIV 2019;6:e463-74. [PMID: 31272663 DOI: 10.1016/S2352-3018(19)30154-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
25 Maokola WM, Ngowi BJ, Mahande MJ, Todd J, Robert M, Msuya SE. Impact of Isoniazid Preventive Therapy on Tuberculosis incidence among people living with HIV: A secondary data analysis using Inverse Probability Weighting of individuals attending HIV care and treatment clinics in Tanzania. PLoS One 2021;16:e0254082. [PMID: 34255776 DOI: 10.1371/journal.pone.0254082] [Reference Citation Analysis]
26 Humphrey JM, Mpofu P, Pettit AC, Musick B, Carter EJ, Messou E, Marcy O, Crabtree-Ramirez B, Yotebieng M, Anastos K, Sterling TR, Yiannoutsos C, Diero L, Wools-Kaloustian K. Mortality Among People With HIV Treated for Tuberculosis Based on Positive, Negative, or No Bacteriologic Test Results for Tuberculosis: The IeDEA Consortium. Open Forum Infect Dis 2020;7:ofaa006. [PMID: 32010735 DOI: 10.1093/ofid/ofaa006] [Reference Citation Analysis]
27 Hermans SM, Grant AD, Chihota V, Lewis JJ, Vynnycky E, Churchyard GJ, Fielding KL. The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. BMC Med 2016;14:45. [PMID: 27004413 DOI: 10.1186/s12916-016-0589-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
28 Kanyerere H, Girma B, Mpunga J, Tayler-Smith K, Harries AD, Jahn A, Chimbwandira FM. Scale-up of ART in Malawi has reduced case notification rates in HIV-positive and HIV-negative tuberculosis. Public Health Action 2016;6:247-51. [PMID: 28123962 DOI: 10.5588/pha.16.0053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
29 Lee SS, Lin HH, Tsai HC, Su IJ, Yang CH, Sun HY, Hung CC, Sy CL, Wu KS, Chen JK, Chen YS, Fang CT. A Clinical Algorithm to Identify HIV Patients at High Risk for Incident Active Tuberculosis: A Prospective 5-Year Cohort Study. PLoS One 2015;10:e0135801. [PMID: 26280669 DOI: 10.1371/journal.pone.0135801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
30 Corbett EL, MacPherson P. Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality. Int J Tuberc Lung Dis 2013;17:1125-38. [PMID: 23928165 DOI: 10.5588/ijtld.13.0117] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
31 Gelaw YA, Williams G, Assefa Y, Asressie M, Soares Magalhães RJ. Sociodemographic profiling of tuberculosis hotspots in Ethiopia, 2014-2017. Trans R Soc Trop Med Hyg 2019;113:379-91. [PMID: 30989204 DOI: 10.1093/trstmh/trz017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
32 Chang CC, Crane M, Zhou J, Mina M, Post JJ, Cameron BA, Lloyd AR, Jaworowski A, French MA, Lewin SR. HIV and co-infections. Immunol Rev 2013;254:114-42. [PMID: 23772618 DOI: 10.1111/imr.12063] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 10.7] [Reference Citation Analysis]
33 Odone A, Amadasi S, White RG, Cohen T, Grant AD, Houben RM. The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis. PLoS One 2014;9:e112017. [PMID: 25391135 DOI: 10.1371/journal.pone.0112017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
34 Pantelic M, Cluver L, Boyes M, Toska E, Kuo C, Moshabela M. Medical pluralism predicts non-ART use among parents in need of ART: a community survey in KwaZulu-Natal, South Africa. AIDS Behav 2015;19:137-44. [PMID: 25034940 DOI: 10.1007/s10461-014-0852-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
35 Granich R, Gupta S, Montaner J, Williams B, Zuniga JM. Pattern, Determinants, and Impact of HIV Spending on Care and Treatment in 38 High-Burden Low- and Middle-Income Countries. J Int Assoc Provid AIDS Care 2016;15:91-100. [PMID: 26715490 DOI: 10.1177/2325957415623261] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
36 Gopalan N, Chandrasekaran P, Swaminathan S, Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther 2016;13:34. [PMID: 27708678 DOI: 10.1186/s12981-016-0118-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
37 Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou SS, Anderson M, McCauley M, Gamble T, Kumarasamy N, Hakim JG, Kumwenda J, Pilotto JH, Godbole SV, Chariyalertsak S, de Melo MG, Mayer KH, Eshleman SH, Piwowar-Manning E, Makhema J, Mills LA, Panchia R, Sanne I, Gallant J, Hoffman I, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Havlir D, Cohen MS; HPTN 052-ACTG Study Team. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014;14:281-90. [PMID: 24602844 DOI: 10.1016/S1473-3099(13)70692-3] [Cited by in Crossref: 309] [Cited by in F6Publishing: 210] [Article Influence: 44.1] [Reference Citation Analysis]
38 Batista Jd, de Albuquerque Mde F, Maruza M, Ximenes RA, Santos ML, Montarroyos UR, de Barros Miranda-Filho D, Lacerda HR, Rodrigues LC. Incidence and risk factors for tuberculosis in people living with HIV: cohort from HIV referral health centers in Recife, Brazil. PLoS One 2013;8:e63916. [PMID: 23675515 DOI: 10.1371/journal.pone.0063916] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
39 Xin HN, Li XW, Zhang L, Li Z, Zhang HR, Yang Y, Li MF, Feng BX, Li HJ, Gao L. Tuberculosis infection testing in HIV-positive men who have sex with men from Xi'an China. Epidemiol Infect 2017;145:498-502. [PMID: 27866487 DOI: 10.1017/S0950268816002703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
40 Lai RPJ, Meintjes G, Wilkinson KA, Graham CM, Marais S, Van der Plas H, Deffur A, Schutz C, Bloom C, Munagala I, Anguiano E, Goliath R, Maartens G, Banchereau J, Chaussabel D, O'Garra A, Wilkinson RJ. HIV-tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling. Nat Commun 2015;6:8451. [PMID: 26399326 DOI: 10.1038/ncomms9451] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 9.8] [Reference Citation Analysis]
41 Musa BM, Musa B, Muhammed H, Ibrahim N, Musa AG. Incidence of tuberculosis and immunological profile of TB/HIV co-infected patients in Nigeria. Ann Thorac Med 2015;10:185-92. [PMID: 26229561 DOI: 10.4103/1817-1737.160838] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
42 Chamla DD, Asadu C, Davies A, de Wagt A, Ilesanmi O, Adeyinka D, Adejuyigbe E. Patching the gaps towards the 90-90-90 targets: outcomes of Nigerian children receiving antiretroviral treatment who are co-infected with tuberculosis. J Int AIDS Soc 2015;18:20251. [PMID: 26639112 DOI: 10.7448/IAS.18.7.20251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
43 Kaplan R, Hermans S, Caldwell J, Jennings K, Bekker LG, Wood R. HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town. BMC Infect Dis 2018;18:356. [PMID: 30064368 DOI: 10.1186/s12879-018-3256-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
44 Tweya H, Feldacker C, Mpunga J, Kanyerere H, Heller T, Ganesh P, Nkosi D, Kalulu M, Sinkala G, Satumba T, Phiri S. The shift in tuberculosis timing among people living with HIV in the course of antiretroviral therapy scale-up in Malawi. J Int AIDS Soc 2019;22:e25240. [PMID: 31038836 DOI: 10.1002/jia2.25240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Menzies NA, Wolf E, Connors D, Bellerose M, Sbarra AN, Cohen T, Hill AN, Yaesoubi R, Galer K, White PJ, Abubakar I, Salomon JA. Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions. Lancet Infect Dis 2018;18:e228-38. [PMID: 29653698 DOI: 10.1016/S1473-3099(18)30134-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
46 Granich R, Gupta S, Hersh B, Williams B, Montaner J, Young B, Zuniga JM. Trends in AIDS Deaths, New Infections and ART Coverage in the Top 30 Countries with the Highest AIDS Mortality Burden; 1990-2013. PLoS One. 2015;10:e0131353. [PMID: 26147987 DOI: 10.1371/journal.pone.0131353] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 14.2] [Reference Citation Analysis]
47 Agizew T, Surie D, Oeltmann JE, Letebele M, Pals S, Mathebula U, Mathoma A, Kassa M, Hamda S, Pono P, Rankgoane-Pono G, Boyd R, Auld A, Finlay A. Tuberculosis preventive treatment opportunities at antiretroviral therapy initiation and follow-up visits. Public Health Action 2020;10:64-9. [PMID: 32639479 DOI: 10.5588/pha.19.0056] [Reference Citation Analysis]
48 Zawedde-Muyanja S, Manabe YC, Musaazi J, Mugabe FR, Ross JM, Hermans S. Anti-retroviral therapy scale-up and its impact on sex-stratified tuberculosis notification trends in Uganda. J Int AIDS Soc 2019;22:e25394. [PMID: 31529618 DOI: 10.1002/jia2.25394] [Reference Citation Analysis]
49 Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, Wilkinson KA, Goliath R, Mathee S, Goemaere E. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384:682–690. [PMID: 24835842 DOI: 10.1016/s0140-6736(14)60162-8] [Cited by in Crossref: 150] [Cited by in F6Publishing: 101] [Article Influence: 21.4] [Reference Citation Analysis]
50 Chakaya JM, Carter EJ, Hopewell PC. Pulmonary specialty training to improve respiratory health in low- and middle-income countries. Needs and challenges. Ann Am Thorac Soc 2015;12:486-90. [PMID: 25714500 DOI: 10.1513/AnnalsATS.201502-071PS] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
51 Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Mosimaneotsile B, Motsamai OI, Shang N, Rose CE, Shepherd J. Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. AIDS 2015;29:351-9. [PMID: 25686683 DOI: 10.1097/QAD.0000000000000535] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
52 Menzies NA, Swartwood N, Testa C, Malyuta Y, Hill AN, Marks SM, Cohen T, Salomon JA. Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States. Epidemiology 2021;32:70-8. [PMID: 33009253 DOI: 10.1097/EDE.0000000000001271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
53 Lemos Lde A, Fiuza ML, Reis RK, Ferrer AC, Gir E, Galvão MT. Adherence to antiretrovirals in people coinfected with the human immunodeficiency virus and tuberculosis. Rev Lat Am Enfermagem 2016;24:e2691. [PMID: 27192416 DOI: 10.1590/1518-8345.0537.2691] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
54 Kanyerere H, Harries AD, Tayler-Smith K, Jahn A, Zachariah R, Chimbwandira FM, Mpunga J. The rise and fall of tuberculosis in Malawi: associations with HIV infection and antiretroviral therapy. Trop Med Int Health 2016;21:101-7. [PMID: 26509352 DOI: 10.1111/tmi.12630] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
55 Hermans S, Boulle A, Caldwell J, Pienaar D, Wood R. Temporal trends in TB notification rates during ART scale-up in Cape Town: an ecological analysis. J Int AIDS Soc 2015;18:20240. [PMID: 26411694 DOI: 10.7448/IAS.18.1.20240] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
56 Takarinda KC, Harries AD, Mutasa-Apollo T, Sandy C, Choto RC, Mabaya S, Mbito C, Timire C. Trend analysis of tuberculosis case notifications with scale-up of antiretroviral therapy and roll-out of isoniazid preventive therapy in Zimbabwe, 2000-2018. BMJ Open 2020;10:e034721. [PMID: 32265241 DOI: 10.1136/bmjopen-2019-034721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Kufa T, Mabuto T, Muchiri E, Charalambous S, Rosillon D, Churchyard G, Harris RC. Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis. PLoS One 2014;9:e111209. [PMID: 25393281 DOI: 10.1371/journal.pone.0111209] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
58 Mbithi A, Gichangi A, Kim AA, Katana A, Weyenga H, Williamson J, Robinson K, Oluoch T, Maina WK, Kellogg TA, De Cock KM; KAIS Study Group. Tuberculosis and HIV at the national level in Kenya: results from the Second Kenya AIDS Indicator Survey. J Acquir Immune Defic Syndr 2014;66 Suppl 1:S106-15. [PMID: 24732814 DOI: 10.1097/QAI.0000000000000120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
59 Dravid A, Natarajan K, Medisetty M, Gawali R, Mahajan U, Kulkarni M, Saraf C, Ghanekar C, Kore S, Rathod N, Dravid M. Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India. BMC Infect Dis 2019;19:714. [PMID: 31409289 DOI: 10.1186/s12879-019-4361-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
60 Granich R, Gupta S. Two diseases, same person: moving toward a combined HIV and tuberculosis continuum of care. Int J STD AIDS 2018;29:873-83. [PMID: 29629649 DOI: 10.1177/0956462418761930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
61 Pathmanathan I, Ahmedov S, Pevzner E, Anyalechi G, Modi S, Kirking H, Cavanaugh JS. TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis 2018;22:596-605. [PMID: 29862942 DOI: 10.5588/ijtld.17.0758] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
62 Ji LD, Xu WN, Chai PF, Zheng W, Qian HX, Xu J. Polymorphisms in the CISH gene are associated with susceptibility to tuberculosis in the Chinese Han population. Infect Genet Evol 2014;28:240-4. [PMID: 25460819 DOI: 10.1016/j.meegid.2014.10.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
63 Coelho L, Cardoso SW, Amancio RT, Moreira RI, Campos DP, Veloso VG, Grinsztejn B, Luz PM. Trends in AIDS-defining opportunistic illnesses incidence over 25 years in Rio de Janeiro, Brazil. PLoS One 2014;9:e98666. [PMID: 24901419 DOI: 10.1371/journal.pone.0098666] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
64 Meintjes G, Kerkhoff AD, Burton R, Schutz C, Boulle A, Van Wyk G, Blumenthal L, Nicol MP, Lawn SD. HIV-Related Medical Admissions to a South African District Hospital Remain Frequent Despite Effective Antiretroviral Therapy Scale-Up. Medicine (Baltimore) 2015;94:e2269. [PMID: 26683950 DOI: 10.1097/MD.0000000000002269] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 7.6] [Reference Citation Analysis]
65 Alemu YM, Awoke W, Wilder-Smith A. Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case-control study. BMJ Open 2016;6:e009058. [PMID: 27084271 DOI: 10.1136/bmjopen-2015-009058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
66 Awasthi AK, Kumar B, Aga MA, Tripathi P, Reddy CS, Kumar P. An efficient and facile synthesis of D-cycloserine substantially free from potential impurities. Chem Heterocycl Comp 2017;53:1248-53. [DOI: 10.1007/s10593-018-2197-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
67 Kufa T, Chihota V, Mngomezulu V, Charalambous S, Verver S, Churchyard G, Borgdorff M. The incidence of tuberculosis among hiv-positive individuals with high CD4 counts: implications for policy. BMC Infect Dis 2016;16:266. [PMID: 27286814 DOI: 10.1186/s12879-016-1598-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
68 Getahun H, Ford N. Tackling the persistent burden of tuberculosis among people living with HIV. J Int AIDS Soc 2016;19:21002. [PMID: 27018421 DOI: 10.7448/IAS.19.1.21002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
69 Harries AD, Lawn SD, Getahun H, Zachariah R, Havlir DV. HIV and tuberculosis--science and implementation to turn the tide and reduce deaths. J Int AIDS Soc 2012;15:17396. [PMID: 22905358 DOI: 10.7448/ias.15.2.17396] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
70 Schön T, Lerm M, Stendahl O. Shortening the ‘short-course’ therapy- insights into host immunity may contribute to new treatment strategies for tuberculosis. J Intern Med 2013;273:368-82. [DOI: 10.1111/joim.12031] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
71 Azanaw MM, Derseh NM, Yetemegn GS, Angaw DA. Incidence and predictors of tuberculosis among HIV patients after initiation of antiretroviral treatment in Ethiopia: a systematic review and meta-analysis. Trop Med Health 2021;49:18. [PMID: 33632342 DOI: 10.1186/s41182-021-00306-2] [Reference Citation Analysis]
72 Pascopella L, Franks J, Marks SM, Salcedo K, Schmitz K, Colson PW, Hirsch-Moverman Y, Flood J, Sayles J. Opportunities for tuberculosis diagnosis and prevention among persons living with HIV: a cross-sectional study of policies and practices at four large Ryan White Program-Funded HIV clinics. PLoS One 2014;9:e101313. [PMID: 25000260 DOI: 10.1371/journal.pone.0101313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
73 Hermans S, Manabe Y. Population-level tuberculosis incidence in the ART era. Lancet Infect Dis 2015;15:997-8. [PMID: 26112076 DOI: 10.1016/S1473-3099(15)00146-2] [Reference Citation Analysis]
74 Gupta RK, Lawn SD, Bekker LG, Caldwell J, Kaplan R, Wood R. Impact of human immunodeficiency virus and CD4 count on tuberculosis diagnosis: analysis of city-wide data from Cape Town, South Africa. Int J Tuberc Lung Dis 2013;17:1014-22. [PMID: 23827024 DOI: 10.5588/ijtld.13.0032] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
75 Tenforde MW, Gupte N, Dowdy DW, Asmuth DM, Balagopal A, Pollard RB, Sugandhavesa P, Lama JR, Pillay S, Cardoso SW, Pawar J, Santos B, Riviere C, Mwelase N, Kanyama C, Kumwenda J, Hakim JG, Kumarasamy N, Bollinger R, Semba RD, Campbell TB, Gupta A; ACTG PEARLS and NWCS 319 Study Group. C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings. PLoS One 2015;10:e0117424. [PMID: 25719208 DOI: 10.1371/journal.pone.0117424] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
76 Lai RP, Nakiwala JK, Meintjes G, Wilkinson RJ. The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol 2013;43:1995-2002. [PMID: 23928963 DOI: 10.1002/eji.201343632] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
77 Gupte AN, Kadam D, Sangle S, Rewari BB, Salvi S, Chavan A, Nimkar S, Golub J, Gupte N, Gupta A, Marbaniang I, Mave V. Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India. BMC Infect Dis 2019;19:914. [PMID: 31664933 DOI: 10.1186/s12879-019-4569-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Sun HY, Hsueh PR, Liu WC, Su YC, Chang SY, Hung CC, Chang SC. Risk of Active Tuberculosis in HIV-Infected Patients in Taiwan with Free Access to HIV Care and a Positive T-Spot.TB Test. PLoS One 2015;10:e0125260. [PMID: 25938227 DOI: 10.1371/journal.pone.0125260] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
79 Harries AD, Kumar AM, Satyanarayana S, Lin Y, Takarinda KC, Tweya H, Reid AJ, Zachariah R. Communicable and non-communicable diseases: connections, synergies and benefits of integrating care. Public Health Action 2015;5:156-7. [PMID: 26393110 DOI: 10.5588/pha.15.0030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
80 Dye C, Williams BG. Tuberculosis decline in populations affected by HIV: a retrospective study of 12 countries in the WHO African Region. Bull World Health Organ 2019;97:405-14. [PMID: 31210678 DOI: 10.2471/BLT.18.228577] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
81 Pretorius C, Menzies NA, Chindelevitch L, Cohen T, Cori A, Eaton JW, Fraser C, Gopalappa C, Hallett TB, Salomon JA, Stover J, White RG, Dodd PJ. The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa: results from three tuberculosis-HIV transmission models. AIDS 2014;28 Suppl 1:S25-34. [PMID: 24468944 DOI: 10.1097/QAD.0000000000000085] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
82 Leung CC, Chan K, Yam WC, Lee MP, Chan CK, Wong KH, Ho PL, Mak I, Tam CM. Poor agreement between diagnostic tests for latent tuberculosis infection among HIV-infected persons in Hong Kong. Respirology 2016;21:1322-9. [PMID: 27121551 DOI: 10.1111/resp.12805] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
83 Floyd K, Glaziou P, Houben RMGJ, Sumner T, White RG, Raviglione M. Global tuberculosis targets and milestones set for 2016-2035: definition and rationale. Int J Tuberc Lung Dis 2018;22:723-30. [PMID: 29914597 DOI: 10.5588/ijtld.17.0835] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 17.0] [Reference Citation Analysis]
84 Surie D, Borgdorff MW, Cain KP, Click ES, DeCock KM, Yuen CM. Assessing the impact of antiretroviral therapy on tuberculosis notification rates among people with HIV: a descriptive analysis of 23 countries in sub-Saharan Africa, 2010-2015. BMC Infect Dis 2018;18:481. [PMID: 30257667 DOI: 10.1186/s12879-018-3387-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
85 Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, Chin DP, Churchyard G, Cox H, Ditiu L, Dybul M, Farrar J, Fauci AS, Fekadu E, Fujiwara PI, Hallett TB, Hanson CL, Harrington M, Herbert N, Hopewell PC, Ikeda C, Jamison DT, Khan AJ, Koek I, Krishnan N, Motsoaledi A, Pai M, Raviglione MC, Sharman A, Small PM, Swaminathan S, Temesgen Z, Vassall A, Venkatesan N, van Weezenbeek K, Yamey G, Agins BD, Alexandru S, Andrews JR, Beyeler N, Bivol S, Brigden G, Cattamanchi A, Cazabon D, Crudu V, Daftary A, Dewan P, Doepel LK, Eisinger RW, Fan V, Fewer S, Furin J, Goldhaber-Fiebert JD, Gomez GB, Graham SM, Gupta D, Kamene M, Khaparde S, Mailu EW, Masini EO, McHugh L, Mitchell E, Moon S, Osberg M, Pande T, Prince L, Rade K, Rao R, Remme M, Seddon JA, Selwyn C, Shete P, Sachdeva KS, Stallworthy G, Vesga JF, Vilc V, Goosby EP. Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet 2019;393:1331-84. [PMID: 30904263 DOI: 10.1016/S0140-6736(19)30024-8] [Cited by in Crossref: 139] [Cited by in F6Publishing: 79] [Article Influence: 69.5] [Reference Citation Analysis]
86 Takarinda KC, Harries AD, Sandy C, Mutasa-Apollo T, Zishiri C. Declining tuberculosis case notification rates with the scale-up of antiretroviral therapy in Zimbabwe. Public Health Action 2016;6:164-8. [PMID: 27695678 DOI: 10.5588/pha.16.0029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
87 Wolday D, Kebede Y, Legesse D, Siraj DS, McBride JA, Kirsch MJ, Striker R. Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade. PLoS One 2020;15:e0233049. [PMID: 32442166 DOI: 10.1371/journal.pone.0233049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
88 Cheng MP, Hirji A, Roth DZ, Cook VJ, Lima VD, Montaner JS, Johnston JC. Tuberculosis in HIV-infected persons in British Columbia during the HAART era. Can J Public Health 2014;105:e258-62. [PMID: 25166127 DOI: 10.17269/cjph.105.4260] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
89 Efsen AM, Schultze A, Post FA, Panteleev A, Furrer H, Miller RF, Losso MH, Toibaro J, Skrahin A, Miro JM, Caylà JA, Girardi E, Bruyand M, Obel N, Podlekareva DN, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group in EuroCoord. Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. PLoS One 2015;10:e0145380. [PMID: 26716686 DOI: 10.1371/journal.pone.0145380] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
90 Yates TA, Ayles H, Leacy FP, Schaap A, Boccia D, Beyers N, Godfrey-Faussett P, Floyd S. Socio-economic gradients in prevalent tuberculosis in Zambia and the Western Cape of South Africa. Trop Med Int Health 2018;23:375-90. [PMID: 29432669 DOI: 10.1111/tmi.13038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
91 Lin WC, Lin HH, Lee SS, Sy CL, Wu KS, Chen JK, Tsai HC, Chen YS. Prevalence of latent tuberculosis infection in persons with and without human immunodeficiency virus infection using two interferon-gamma release assays and tuberculin skin test in a low human immunodeficiency virus prevalence, intermediate tuberculosis-burden country. J Microbiol Immunol Infect 2016;49:729-36. [PMID: 25442858 DOI: 10.1016/j.jmii.2014.08.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
92 Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P, Thomason M, Mugyenyi P, Musoke P, Kekitiinwa A, Munderi P, Nathoo K, Prendergast AJ, Walker AS, Gibb DM; ARROW Trial Team. Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy. BMC Med 2016;14:50. [PMID: 27004529 DOI: 10.1186/s12916-016-0593-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
93 Chaisson RE, Golub JE. Preventing tuberculosis in people with HIV-no more excuses. Lancet Glob Health 2017;5:e1048-9. [PMID: 29025618 DOI: 10.1016/S2214-109X(17)30390-X] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
94 Coelho LE, Cardoso SW, Amancio RT, Moreira RI, Ribeiro SR, Coelho AB, Campos DP, Veloso VG, Grinsztejn B, Luz PM. Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil. BMC Infect Dis 2016;16:134. [PMID: 27001753 DOI: 10.1186/s12879-016-1462-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
95 Pia Sormani M, Wolff R, Lang S, Duffy S, Hyde R, Kinter E, Wakeford C, Giovannoni G, Kleijnen J. Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis. Neurol Ther 2020;9:335-58. [PMID: 32978726 DOI: 10.1007/s40120-020-00213-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Kong D, Watt JP, Marks SM, Flood JM. Timely HIV diagnosis and HIV/TB comanagement among California patients in 2008. Public Health Rep 2014;129:170-7. [PMID: 24587552 DOI: 10.1177/003335491412900211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
97 Lima VD, Granich R, Phillips P, Williams B, Montaner JS. Potential impact of the US President's Emergency Plan for AIDS relief on the tuberculosis/HIV coepidemic in selected Sub-Saharan African countries. J Infect Dis 2013;208:2075-84. [PMID: 23911712 DOI: 10.1093/infdis/jit406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
98 Lai RP, Meintjes G, Wilkinson RJ. HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome. Semin Immunopathol 2016;38:185-98. [PMID: 26423994 DOI: 10.1007/s00281-015-0532-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
99 Kerschberger B, Schomaker M, Telnov A, Vambe D, Kisyeri N, Sikhondze W, Pasipamire L, Ngwenya SM, Rusch B, Ciglenecki I, Boulle A. Decreased risk of HIV-associated TB during antiretroviral therapy expansion in rural Eswatini from 2009 to 2016: a cohort and population-based analysis. Trop Med Int Health 2019;24:1114-27. [PMID: 31310029 DOI: 10.1111/tmi.13290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Furin J, Akugizibwe P, Ditiu L, Gray G, Palmero D, Zaidi S. No one with HIV should die from tuberculosis. Lancet 2015;386:e48-50. [PMID: 26515682 DOI: 10.1016/S0140-6736(15)00319-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
101 Lee SS, Meintjes G, Kamarulzaman A, Leung CC. Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons. Respirology 2013;18:912-22. [PMID: 23682586 DOI: 10.1111/resp.12120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
102 Coelho LE, Luz PM. Life-expectancy with HIV in Latin America and the Caribbean. Lancet HIV 2021;8:e247-8. [PMID: 33891878 DOI: 10.1016/S2352-3018(21)00050-3] [Reference Citation Analysis]
103 Muyaya LM, Young T, Loveday M. Predictors of mortality in adults on treatment for human immunodeficiency virus-associated tuberculosis in Botswana: A retrospective cohort study. Medicine (Baltimore) 2018;97:e0486. [PMID: 29668628 DOI: 10.1097/MD.0000000000010486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
104 Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, Cohn S, Efron A, Chaisson RE, Golub JE. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis 2013;13:852-8. [PMID: 23954450 DOI: 10.1016/S1473-3099(13)70187-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
105 Yates TA, Khan PY, Knight GM, Taylor JG, McHugh TD, Lipman M, White RG, Cohen T, Cobelens FG, Wood R, Moore DA, Abubakar I. The transmission of Mycobacterium tuberculosis in high burden settings. Lancet Infect Dis 2016;16:227-38. [PMID: 26867464 DOI: 10.1016/S1473-3099(15)00499-5] [Cited by in Crossref: 89] [Cited by in F6Publishing: 62] [Article Influence: 17.8] [Reference Citation Analysis]
106 Harries AD, Suthar AB, Takarinda KC, Tweya H, Kyaw NT, Tayler-Smith K, Zachariah R. Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible? F1000Res 2016;5:2328. [PMID: 27703672 DOI: 10.12688/f1000research.9247.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
107 Kumarasamy N, Poongulali S, Bollaerts A, Moris P, Beulah FE, Ayuk LN, Demoitié MA, Jongert E, Ofori-Anyinam O. A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults. Medicine (Baltimore) 2016;95:e2459. [PMID: 26817879 DOI: 10.1097/MD.0000000000002459] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
108 Liu E, Makubi A, Drain P, Spiegelman D, Sando D, Li N, Chalamilla G, Sudfeld CR, Hertzmark E, Fawzi WW. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy. AIDS 2015;29:1391-9. [PMID: 26091295 DOI: 10.1097/QAD.0000000000000705] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 8.4] [Reference Citation Analysis]
109 Basu S, Andrews J. Complexity in mathematical models of public health policies: a guide for consumers of models. PLoS Med 2013;10:e1001540. [PMID: 24204214 DOI: 10.1371/journal.pmed.1001540] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
110 Borgdorff MW, Cain KP, DeCock KM. The molecular epidemiology of tuberculosis in settings with a high HIV prevalence: implications for control. J Infect Dis 2015;211:8-9. [PMID: 25053740 DOI: 10.1093/infdis/jiu404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
111 Kendall EA, Azman AS, Maartens G, Boulle A, Wilkinson RJ, Dowdy DW, Rangaka MX. Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. AIDS 2019;33:525-36. [PMID: 30325773 DOI: 10.1097/QAD.0000000000002053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
112 Norrby M, Wannheden C, Ekström AM, Berggren I, Lindquist L. Incidence of tuberculosis and the need of prophylactic treatment in persons living with HIV in Stockholm during the era of anti-retroviral therapy 1996-2013. Infect Dis (Lond) 2018;50:807-16. [PMID: 30362392 DOI: 10.1080/23744235.2018.1486511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
113 Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076. [PMID: 27784885 DOI: 10.1038/nrdp.2016.76] [Cited by in Crossref: 405] [Cited by in F6Publishing: 352] [Article Influence: 81.0] [Reference Citation Analysis]
114 Abel L, El-Baghdadi J, Bousfiha AA, Casanova JL, Schurr E. Human genetics of tuberculosis: a long and winding road. Philos Trans R Soc Lond B Biol Sci 2014;369:20130428. [PMID: 24821915 DOI: 10.1098/rstb.2013.0428] [Cited by in Crossref: 106] [Cited by in F6Publishing: 91] [Article Influence: 15.1] [Reference Citation Analysis]
115 Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015;46:1563-76. [PMID: 26405286 DOI: 10.1183/13993003.01245-2015] [Cited by in F6Publishing: 277] [Reference Citation Analysis]
116 Kagujje M, Mubiana ML, Mwamba E, Muyoyeta M. Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons. BMC Public Health 2019;19:1329. [PMID: 31640657 DOI: 10.1186/s12889-019-7652-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Sadirova D, Grigoryan R, Parpieva N, Barotova V, Trubnikov A, Kalandarova L, Gadoev J, Mukhtarov D, Buziashvili M, Tukvadze N, Hovhannesyan A, Dadu A. Incidence Rate and Risk Factors for Tuberculosis among People Living with HIV: A 2015-2017 Cohort from Tashkent, Uzbekistan. Int J Environ Res Public Health 2021;18:5746. [PMID: 34071899 DOI: 10.3390/ijerph18115746] [Reference Citation Analysis]
118 Wong NS, Leung CC, Chan KCW, Chan WK, Lin AWC, Lee SS. A longitudinal study on latent TB infection screening and its association with TB incidence in HIV patients. Sci Rep 2019;9:10093. [PMID: 31300686 DOI: 10.1038/s41598-019-46570-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
119 Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P, Bates M, Colagiuri R, Zijenah L, Swaminathan S, Memish ZA, Pletschette M, Hoelscher M, Abubakar I, Hasan R, Zafar A, Pantaleo G, Craig G, Kim P, Maeurer M, Schito M, Zumla A. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis 2013;13:436-48. [PMID: 23531392 DOI: 10.1016/S1473-3099(13)70015-X] [Cited by in Crossref: 146] [Cited by in F6Publishing: 85] [Article Influence: 18.3] [Reference Citation Analysis]
120 Fitzpatrick ME, Kunisaki KM, Morris A. Pulmonary disease in HIV-infected adults in the era of antiretroviral therapy. AIDS 2018;32:277-92. [PMID: 29194119 DOI: 10.1097/QAD.0000000000001712] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 13.5] [Reference Citation Analysis]
121 Ferrand H, Crockett F, Naccache JM, Rioux C, Mayaud C, Yazdanpanah Y, Cadranel J. [Pulmonary manifestations in HIV-infected patients: a diagnostic approach]. Rev Mal Respir 2014;31:903-15. [PMID: 25496788 DOI: 10.1016/j.rmr.2014.04.106] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
122 Courtenay-Quirk C, Date A, Bachanas P, Baggaley R, Getahun H, Nelson L, Granich R. Expanding human immunodeficiency virus testing and counseling to reach tuberculosis clients' partners and families. Int J Tuberc Lung Dis 2015;19:1414-6. [PMID: 26614180 DOI: 10.5588/ijtld.15.0007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
123 Dodd PJ, Prendergast AJ, Beecroft C, Kampmann B, Seddon JA. The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis. Thorax 2017;72:559-75. [PMID: 28115682 DOI: 10.1136/thoraxjnl-2016-209421] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
124 Maemun S, Mariana N, Rusli A, Mahkota R, Purnama TB. Early Initiation of ARV Therapy Among TB-HIV Patients in Indonesia Prolongs Survival Rates! J Epidemiol Glob Health 2020;10:164-7. [PMID: 32538033 DOI: 10.2991/jegh.k.200102.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Ahmed A, Mekonnen D, Shiferaw AM, Belayneh F, Yenit MK. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study. BMJ Open 2018;8:e016961. [PMID: 29437750 DOI: 10.1136/bmjopen-2017-016961] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
126 Granich R, Williams BG. Treatment as prevention trials and ending AIDS: what do we know, when did we know it, and what do we do now? Curr Opin HIV AIDS 2019;14:514-20. [PMID: 31567399 DOI: 10.1097/COH.0000000000000582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
127 Alvarez-Uria G, Pakam R, Midde M, Naik PK. Optimal Duration of Daily Antituberculosis Therapy before Switching to DOTS Intermittent Therapy to Reduce Mortality in HIV Infected Patients: A Duration-Response Analysis Using Restricted Cubic Splines. Int Sch Res Notices 2014;2014:704980. [PMID: 27433510 DOI: 10.1155/2014/704980] [Reference Citation Analysis]
128 Diedrich CR, O'Hern J, Gutierrez MG, Allie N, Papier P, Meintjes G, Coussens AK, Wainwright H, Wilkinson RJ. Relationship Between HIV Coinfection, Interleukin 10 Production, and Mycobacterium tuberculosis in Human Lymph Node Granulomas. J Infect Dis 2016;214:1309-18. [PMID: 27462092 DOI: 10.1093/infdis/jiw313] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
129 Tornheim JA, Dooley KE. Tuberculosis Associated with HIV Infection. Microbiol Spectr 2017;5. [PMID: 28233512 DOI: 10.1128/microbiolspec.TNMI7-0028-2016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
130 Nemes E, Scriba TJ, Hatherill M. Prospects for a vaccine to prevent HIV-related tuberculosis. Curr Opin HIV AIDS 2018;13:522-7. [PMID: 30080682 DOI: 10.1097/COH.0000000000000496] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
131 Mutembo S, Mutanga JN, Musokotwane K, Alisheke L, Whalen CC. Antiretroviral therapy improves survival among TB-HIV co-infected patients who have CD4+ T-cell count above 350cells/mm3. BMC Infect Dis 2016;16:572. [PMID: 27751168 DOI: 10.1186/s12879-016-1916-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
132 Davies MA, Pinto J, Bras M. Getting to 90-90-90 in paediatric HIV: What is needed? J Int AIDS Soc 2015;18:20770. [PMID: 28326130 DOI: 10.7448/IAS.18.7.20770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
133 Capocci SJ, Sewell J, Smith C, Cropley I, Bhagani S, Solamalai A, Morris S, Abubakar I, Johnson MA, Lipman MCI. Cost effectiveness of testing HIV infected individuals for TB in a low TB/HIV setting. J Infect 2020;81:289-96. [PMID: 32473234 DOI: 10.1016/j.jinf.2020.05.055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
134 Chang KC, Yew WW. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. Respirology 2013;18:8-21. [PMID: 22943408 DOI: 10.1111/j.1440-1843.2012.02257.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
135 Harries AD, Kumar AMV, Satyanarayana S, Takarinda KC, Timire C, Dlodlo RA. Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up. Expert Rev Respir Med 2020;14:195-208. [PMID: 31760848 DOI: 10.1080/17476348.2020.1694907] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
136 McNairy ML, Cohen M, El-Sadr WM. Antiretroviral therapy for prevention is a combination strategy. Curr HIV/AIDS Rep 2013;10:152-8. [PMID: 23371351 DOI: 10.1007/s11904-013-0152-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
137 Ellis PK, Martin WJ, Dodd PJ. CD4 count and tuberculosis risk in HIV-positive adults not on ART: a systematic review and meta-analysis. PeerJ 2017;5:e4165. [PMID: 29259846 DOI: 10.7717/peerj.4165] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
138 Bachmann MO, Timmerman V, Fairall LR. Effect of antiretroviral treatment on the risk of tuberculosis during South Africa's programme expansion. AIDS 2015;29:2261-8. [PMID: 26544699 DOI: 10.1097/QAD.0000000000000806] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
139 Cameron NA, Molsberry R, Pierce JB, Perak AM, Grobman WA, Allen NB, Greenland P, Lloyd-Jones DM, Khan SS. Pre-Pregnancy Hypertension Among Women in Rural and Urban Areas of the United States. J Am Coll Cardiol 2020;76:2611-9. [PMID: 33183896 DOI: 10.1016/j.jacc.2020.09.601] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
140 Kerkhoff AD, Kranzer K, Samandari T, Nakiyingi-Miiro J, Whalen CC, Harries AD, Lawn SD. Systematic review of TST responses in people living with HIV in under-resourced settings: implications for isoniazid preventive therapy. PLoS One 2012;7:e49928. [PMID: 23209621 DOI: 10.1371/journal.pone.0049928] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
141 Nyathi S, Dlodlo RA, Satyanarayana S, Takarinda KC, Tweya H, Hove S, Matambo R, Mandewo W, Nyathi K, Sibanda E, Harries AD. Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe. PLoS One 2019;14:e0223076. [PMID: 31581271 DOI: 10.1371/journal.pone.0223076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
142 Günther G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clin Med (Lond) 2014;14:279-85. [PMID: 24889573 DOI: 10.7861/clinmedicine.14-3-279] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 10.0] [Reference Citation Analysis]
143 Yuen CM, Weyenga HO, Kim AA, Malika T, Muttai H, Katana A, Nganga L, Cain KP, De Cock KM. Comparison of trends in tuberculosis incidence among adults living with HIV and adults without HIV--Kenya, 1998-2012. PLoS One 2014;9:e99880. [PMID: 24937804 DOI: 10.1371/journal.pone.0099880] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
144 Pretorius C, Glaziou P, Dodd PJ, White R, Houben R. Using the TIME model in Spectrum to estimate tuberculosis-HIV incidence and mortality. AIDS 2014;28 Suppl 4:S477-87. [PMID: 25406751 DOI: 10.1097/QAD.0000000000000484] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
145 Ross JM, Badje A, Rangaka MX, Walker AS, Shapiro AE, Thomas KK, Anglaret X, Eholie S, Gabillard D, Boulle A, Maartens G, Wilkinson RJ, Ford N, Golub JE, Williams BG, Barnabas RV. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV 2021;8:e8-e15. [PMID: 33387480 DOI: 10.1016/S2352-3018(20)30299-X] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
146 Zeldow B, Kim S, McSherry G, Cotton MF, Jean-Philippe P, Violari A, Bobat R, Nachman S, Mofenson LM, Madhi SA, Mitchell C. Use of antiretrovirals in HIV-infected children in a tuberculosis prevention trial: IMPAACT P1041. Int J Tuberc Lung Dis 2017;21:38-45. [PMID: 28157463 DOI: 10.5588/ijtld.16.0149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
147 Takarinda KC, Choto R, Sandy C, Apollo T, Duri C, Dube F, Mpofu A, Timire C, Mugurungi O, Makaza V, Tapera R, Harries AD. How well does the process of screening and diagnosis work for HIV-infected persons identified with presumptive tuberculosis who are attending HIV care and treatment clinics in Harare city, Zimbabwe? Trans R Soc Trop Med Hyg 2018;112:450-7. [PMID: 30032237 DOI: 10.1093/trstmh/try073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
148 Gupta S, Abimbola T, Date A, Suthar AB, Bennett R, Sangrujee N, Granich R. Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV. Int J Tuberc Lung Dis 2014;18:1159-65. [PMID: 25216828 DOI: 10.5588/ijtld.13.0571] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
149 Jones CW, Keil LG, Weaver MA, Platts-Mills TF. Clinical trials registries are under-utilized in the conduct of systematic reviews: a cross-sectional analysis. Syst Rev 2014;3:126. [PMID: 25348628 DOI: 10.1186/2046-4053-3-126] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
150 van Leth F, Evenblij K, Wit F, Kiers A, Sprenger H, Verhagen M, Hillebregt M, Kalisvaart N, Schimmel H, Verbon A. TB-HIV co-infection in the Netherlands: estimating prevalence and under-reporting in national registration databases using a capture-recapture analysis. J Epidemiol Community Health 2016;70:556-60. [PMID: 26700301 DOI: 10.1136/jech-2015-206680] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
151 Okonko IO, Ejike IU, Innocent-Adiele C, Cookey TI. HIV coinfections with tuberculosis among HIV-1 infected individuals in old cross river state, Nigeria. J Immunoassay Immunochem 2020;41:245-56. [PMID: 31957554 DOI: 10.1080/15321819.2020.1717527] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
152 Khayat M, Fan H, Vali Y. COVID-19 promoting the development of active tuberculosis in a patient with latent tuberculosis infection: A case report. Respir Med Case Rep 2021;32:101344. [PMID: 33495728 DOI: 10.1016/j.rmcr.2021.101344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Mai TQ, Martinez E, Menon R, Van Anh NT, Hien NT, Lan NH, Giang DC, Hang PT, Thuong PH, Van Huan H, Hoang NP, Nhung NV, Hoa NB, Marais BJ, Sintchenko V. Tuberculosis risk factors and Mycobacterium tuberculosis transmission among HIV-infected patients in Vietnam. Tuberculosis (Edinb) 2019;115:67-75. [PMID: 30948179 DOI: 10.1016/j.tube.2019.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Fenner L, Ballif M, Graber C, Nhandu V, Dusingize JC, Cortes CP, Carriquiry G, Anastos K, Garone D, Jong E, Gnokoro JC, Sued O, Ajayi S, Diero L, Wools-Kaloustian K, Kiertiburanakul S, Castelnuovo B, Lewden C, Durier N, Sterling TR, Egger M; International epidemiological Databases to Evaluate AIDS (IeDEA). Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS One 2013;8:e77697. [PMID: 24147059 DOI: 10.1371/journal.pone.0077697] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
155 Kerkhoff AD, Wood R, Cobelens FG, Gupta-Wright A, Bekker LG, Lawn SD. The predictive value of current haemoglobin levels for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: a cohort study. BMC Med 2015;13:70. [PMID: 25889688 DOI: 10.1186/s12916-015-0320-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
156 Melgar M, Shiraishi RW, Tende C, Mwanza S, Mulenga J, Khondowe S, Mwakazanga D, Kapungu K, Tembo M, Nota A, Lungu P, Moore B, Podewils LJ. Assessment of the tuberculosis case-finding and prevention cascade among people living with HIV in Zambia - 2018: a cross-sectional cluster survey. BMC Public Health 2021;21:859. [PMID: 33947361 DOI: 10.1186/s12889-021-10929-z] [Reference Citation Analysis]
157 Mekonnen D, Derbie A, Mekonnen H, Zenebe Y. Profile and treatment outcomes of patients with tuberculosis in Northeastern Ethiopia: a cross sectional study. Afr Health Sci 2016;16:663-70. [PMID: 27917197 DOI: 10.4314/ahs.v16i3.4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
158 Harries AD, Kumar AMV, Satyanarayana S, Thekkur P, Lin Y, Dlodlo RA, Khogali M, Zachariah R. The Growing Importance of Tuberculosis Preventive Therapy and How Research and Innovation Can Enhance Its Implementation on the Ground. Trop Med Infect Dis 2020;5:E61. [PMID: 32316300 DOI: 10.3390/tropicalmed5020061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
159 Harries AD, Kumar AMV, Satyanarayana S, Thekkur P, Lin Y, Dlodlo RA, Zachariah R. How Can Operational Research Help to Eliminate Tuberculosis in the Asia Pacific Region? Trop Med Infect Dis 2019;4:E47. [PMID: 30875884 DOI: 10.3390/tropicalmed4010047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
160 Aemro A, Jember A, Anlay DZ. Incidence and predictors of tuberculosis occurrence among adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: retrospective follow-up study. BMC Infect Dis 2020;20:245. [PMID: 32216747 DOI: 10.1186/s12879-020-04959-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Vignesh R, Kumarasamy N, Lim A, Solomon S, Murugavel KG, Balakrishnan P, Solomon SS, Mayer KH, Swathirajan CR, Chandrasekaran E, Pradeep A, Poongulali S, Benson CA, French MA. TB-IRIS after initiation of antiretroviral therapy is associated with expansion of preexistent Th1 responses against Mycobacterium tuberculosis antigens. J Acquir Immune Defic Syndr 2013;64:241-8. [PMID: 23774879 DOI: 10.1097/QAI.0b013e31829f6df2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.9] [Reference Citation Analysis]
162 Varghese GM, Janardhanan J, Ralph R, Abraham OC. The Twin Epidemics of Tuberculosis and HIV. Curr Infect Dis Rep 2013;15:77-84. [DOI: 10.1007/s11908-012-0311-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
163 Delva W, Fleming Y, Chingandu L. When to start ART in Africa--primarily guided by RCTs or patient autonomy? J Int AIDS Soc 2013;16:18756. [PMID: 23849225 DOI: 10.7448/IAS.16.1.18756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
164 Collin SM, Wurie F, Muzyamba MC, de Vries G, Lönnroth K, Migliori GB, Abubakar I, Anderson SR, Zenner D. Effectiveness of interventions for reducing TB incidence in countries with low TB incidence: a systematic review of reviews. Eur Respir Rev 2019;28:180107. [PMID: 31142548 DOI: 10.1183/16000617.0107-2018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
165 Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS 2015;29:1987-2002. [PMID: 26266773 DOI: 10.1097/QAD.0000000000000802] [Cited by in Crossref: 171] [Cited by in F6Publishing: 128] [Article Influence: 34.2] [Reference Citation Analysis]
166 Vynnycky E, Sumner T, Fielding KL, Lewis JJ, Cox AP, Hayes RJ, Corbett EL, Churchyard GJ, Grant AD, White RG. Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy. Am J Epidemiol 2015;181:619-32. [PMID: 25792607 DOI: 10.1093/aje/kwu320] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
167 Regazzi M, Carvalho AC, Villani P, Matteelli A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin Pharmacokinet 2014;53:489-507. [PMID: 24777631 DOI: 10.1007/s40262-014-0144-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
168 Martin-Iguacel R, Llibre JM, Pedersen C, Obel N, Stærke NB, Åhsberg J, Ørsted I, Holden I, Kronborg G, Mohey R, Rasmussen LD, Johansen IS. Tuberculosis incidence and mortality in people living with human immunodeficiency virus: a Danish nationwide cohort study. Clin Microbiol Infect 2021:S1198-743X(21)00431-6. [PMID: 34438070 DOI: 10.1016/j.cmi.2021.07.036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Ji YJ, Liang PP, Shen JY, Sun JJ, Yang JY, Chen J, Qi TK, Wang ZY, Song W, Tang Y, Liu L, Zhang RF, Shen YZ, Lu HZ. Risk factors affecting the mortality of HIV-infected patients with pulmonary tuberculosis in the cART era: a retrospective cohort study in China. Infect Dis Poverty 2018;7:25. [PMID: 29587840 DOI: 10.1186/s40249-018-0405-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
170 Dodd PJ, Knight GM, Lawn SD, Corbett EL, White RG. Predicting the long-term impact of antiretroviral therapy scale-up on population incidence of tuberculosis. PLoS One 2013;8:e75466. [PMID: 24069418 DOI: 10.1371/journal.pone.0075466] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
171 Mchunu G, van Griensven J, Hinderaker SG, Kizito W, Sikhondze W, Manzi M, Dlamini T, Harries AD. High mortality in tuberculosis patients despite HIV interventions in Swaziland. Public Health Action 2016;6:105-10. [PMID: 27358803 DOI: 10.5588/pha.15.0081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
172 Murray JF. Epidemiology of Human Immunodeficiency Virus–Associated Pulmonary Disease. Clinics in Chest Medicine 2013;34:165-79. [DOI: 10.1016/j.ccm.2013.02.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
173 Garg RK, Jain A, Malhotra HS, Agrawal A, Garg R. Drug-resistant tuberculous meningitis. Expert Review of Anti-infective Therapy 2014;11:605-21. [DOI: 10.1586/eri.13.39] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
174 Lawn SD, Wilkinson RJ. ART and prevention of HIV-associated tuberculosis. Lancet HIV 2015;2:e221-2. [PMID: 26423189 DOI: 10.1016/S2352-3018(15)00081-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
175 Lundgren JD, Babiker AG, Gordin FM, Borges ÁH, Neaton JD. When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Med 2013;11:148. [PMID: 23767777 DOI: 10.1186/1741-7015-11-148] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
176 Ogoina D, Finomo F, Harry T, Inatimi O, Ebuenyi I, Tariladei WW, Afolayan AA. Factors Associated with Timing of Initiation of Antiretroviral Therapy among HIV-1 Infected Adults in the Niger Delta Region of Nigeria. PLoS One 2015;10:e0125665. [PMID: 25933356 DOI: 10.1371/journal.pone.0125665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
177 Flick RJ, Munthali A, Simon K, Hosseinipour M, Kim MH, Mlauzi L, Kazembe PN, Ahmed S. Assessing infection control practices to protect health care workers and patients in Malawi from nosocomial transmission of Mycobacterium tuberculosis. PLoS One 2017;12:e0189140. [PMID: 29211793 DOI: 10.1371/journal.pone.0189140] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
178 Tiberi S, Carvalho AC, Sulis G, Vaghela D, Rendon A, Mello FC, Rahman A, Matin N, Zumla A, Pontali E. The cursed duet today: Tuberculosis and HIV-coinfection. Presse Med 2017;46:e23-39. [PMID: 28256380 DOI: 10.1016/j.lpm.2017.01.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
179 Jambo KC, Banda DH, Afran L, Kankwatira AM, Malamba RD, Allain TJ, Gordon SB, Heyderman RS, Russell DG, Mwandumba HC. Asymptomatic HIV-infected individuals on antiretroviral therapy exhibit impaired lung CD4(+) T-cell responses to mycobacteria. Am J Respir Crit Care Med. 2014;190:938-947. [PMID: 25225948 DOI: 10.1164/rccm.201405-0864oc] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
180 Prabowo SA, Gröschel MI, Schmidt EDL, Skrahina A, Mihaescu T, Hastürk S, Mitrofanov R, Pimkina E, Visontai I, de Jong B, Stanford JL, Cardona P, Kaufmann SHE, van der Werf TS. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 2013;202:95-104. [DOI: 10.1007/s00430-012-0278-6] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
181 Dierberg KL, Chaisson RE. Human immunodeficiency virus-associated tuberculosis: update on prevention and treatment. Clin Chest Med 2013;34:217-28. [PMID: 23702172 DOI: 10.1016/j.ccm.2013.02.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
182 Sarwar G, Reza M, Khan MNM, Gourab G, Rahman M, Rana AKMM, Khan SM, Irfan SD, Ahmed S, Banu RS, Banu S, Khan SI. Developing and testing community-based tuberculosis (TB) screening intervention to increase TB referral, case detection and knowledge among sexual minority people in urban Bangladesh: a mixed-method study protocol. BMJ Open 2020;10:e037371. [PMID: 32963067 DOI: 10.1136/bmjopen-2020-037371] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
183 Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, Zumla AI, Maeurer M. Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review. Lancet Respir Med. 2014;2:301-320. [PMID: 24717627 DOI: 10.1016/s2213-2600(14)70033-5] [Cited by in Crossref: 156] [Cited by in F6Publishing: 79] [Article Influence: 22.3] [Reference Citation Analysis]
184 Gupta S, Granich R, Suthar AB, Smyth C, Baggaley R, Sculier D, Date A, Desai MA, Lule F, Raizes E, Blanc L, Hirnschall G. Global policy review of antiretroviral therapy eligibility criteria for treatment and prevention of HIV and tuberculosis in adults, pregnant women, and serodiscordant couples. J Acquir Immune Defic Syndr 2013;62:e87-97. [PMID: 23187942 DOI: 10.1097/QAI.0b013e31827e4992] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
185 Xu W, Snell LM, Guo M, Boukhaled G, Macleod BL, Li M, Tullius MV, Guidos CJ, Tsao MS, Divangahi M, Horwitz MA, Liu J, Brooks DG. Early innate and adaptive immune perturbations determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection. Immunity 2021;54:526-541.e7. [PMID: 33515487 DOI: 10.1016/j.immuni.2021.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
186 Saavedra A, Campinha-Bacote N, Hajjar M, Kenu E, Gillani FS, Obo-Akwa A, Lartey M, Kwara A. Causes of death and factors associated with early mortality of HIV-infected adults admitted to Korle-Bu Teaching Hospital. Pan Afr Med J 2017;27:48. [PMID: 28819470 DOI: 10.11604/pamj.2017.27.48.8917] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
187 Harris RC, Sumner T, Knight GM, Zhang H, White RG. Potential impact of tuberculosis vaccines in China, South Africa, and India. Sci Transl Med 2020;12:eaax4607. [PMID: 33028708 DOI: 10.1126/scitranslmed.aax4607] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
188 Karageorgiou V, Lambrinoudaki I, Goulis DG. Menopause in women with multiple sclerosis: A systematic review. Maturitas 2020;135:68-73. [PMID: 32252967 DOI: 10.1016/j.maturitas.2020.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
189 Alemu YM, Andargie G, Gebeye E. High Incidence of Tuberculosis in the Absence of Isoniazid and Cotrimoxazole Preventive Therapy in Children Living with HIV in Northern Ethiopia: A Retrospective Follow-Up Study. PLoS One 2016;11:e0152941. [PMID: 27070435 DOI: 10.1371/journal.pone.0152941] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
190 Kanyerere H, Mganga A, Harries AD, Tayler-Smith K, Jahn A, Chimbwandira FM, Mpunga J. Decline in national tuberculosis notifications with national scale-up of antiretroviral therapy in Malawi. Public Health Action 2014;4:113-5. [PMID: 26399210 DOI: 10.5588/pha.14.0018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
191 Brown J, Roy A, Harris R, Filson S, Johnson M, Abubakar I, Lipman M. Respiratory symptoms in people living with HIV and the effect of antiretroviral therapy: a systematic review and meta-analysis. Thorax 2017;72:355-66. [PMID: 27965402 DOI: 10.1136/thoraxjnl-2016-208657] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
192 Chehab JC, Vilakazi-Nhlapo AK, Vranken P, Peters A, Klausner JD. Current integration of tuberculosis (TB) and HIV services in South Africa, 2011. PLoS One 2013;8:e57791. [PMID: 23469242 DOI: 10.1371/journal.pone.0057791] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
193 Yotebieng M, Tabala M, Batumbula ML, Wenzi L, Basaki E, Mungoyo E, Mangala R, Behets F. Impact of WHO 2010 Guidelines on Antiretroviral Therapy Initiation among Patients with HIV-Associated Tuberculosis in Clinics with and without Onsite HIV Services in the Democratic Republic of Congo. Tuberc Res Treat 2016;2016:1027570. [PMID: 27595020 DOI: 10.1155/2016/1027570] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
194 Khan PY, Crampin AC, Mzembe T, Koole O, Fielding KL, Kranzer K, Glynn JR. Does antiretroviral treatment increase the infectiousness of smear-positive pulmonary tuberculosis? Int J Tuberc Lung Dis 2017;21:1147-54. [PMID: 29037295 DOI: 10.5588/ijtld.17.0162] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
195 Johnson KT, Churchyard GJ, Sohn H, Dowdy DW. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. Clin Infect Dis 2018;67:1072-8. [PMID: 29617965 DOI: 10.1093/cid/ciy230] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
196 González Fernández L, Casas EC, Singh S, Churchyard GJ, Brigden G, Gotuzzo E, Vandevelde W, Sahu S, Ahmedov S, Kamarulzaman A, Ponce-de-León A, Grinsztejn B, Swindells S. New opportunities in tuberculosis prevention: implications for people living with HIV. J Int AIDS Soc 2020;23:e25438. [PMID: 31913556 DOI: 10.1002/jia2.25438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
197 Lyadova I, Nikitina I. Cell Differentiation Degree as a Factor Determining the Role for Different T-Helper Populations in Tuberculosis Protection. Front Immunol 2019;10:972. [PMID: 31134070 DOI: 10.3389/fimmu.2019.00972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
198 International Advisory Panel on HIV Care Continuum Optimization. IAPAC Guidelines for Optimizing the HIV Care Continuum for Adults and Adolescents. J Int Assoc Provid AIDS Care 2015;14 Suppl 1:S3-S34. [PMID: 26527218 DOI: 10.1177/2325957415613442] [Cited by in Crossref: 53] [Cited by in F6Publishing: 61] [Article Influence: 8.8] [Reference Citation Analysis]
199 Saraceni V, Cohn S, Cavalcante SC, Pacheco AG, Moulton LH, Chaisson RE, Durovni B, Golub JE. Prevalent tuberculosis at HIV diagnosis in Rio de Janeiro, Brazil: the TB/HIV in Rio (THRio) Cohort. J Acquir Immune Defic Syndr 2014;67:98-101. [PMID: 24933097 DOI: 10.1097/QAI.0000000000000247] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
200 Nagu TJ, Aboud S, Mwiru R, Matee MI, Rao M, Fawzi WW, Zumla A, Maeurer MJ, Mugusi F. Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy. Int J Infect Dis 2017;56:39-44. [PMID: 28161460 DOI: 10.1016/j.ijid.2017.01.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
201 Harries AD, Lawn SD, Suthar AB, Granich R. Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation. Lancet Infect Dis 2015;15:1492-6. [PMID: 26515525 DOI: 10.1016/S1473-3099(15)00242-X] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
202 van Halsema CL, Okhai H, Hill T, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study. Incidence of and risk factors for tuberculosis among people with HIV on antiretroviral therapy in the United Kingdom. AIDS 2020;34:1813-21. [PMID: 32501837 DOI: 10.1097/QAD.0000000000002599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Anígilájé EA, Aderibigbe SA, Adeoti AO, Nweke NO. Tuberculosis, before and after Antiretroviral Therapy among HIV-Infected Children in Nigeria: What Are the Risk Factors? PLoS One 2016;11:e0156177. [PMID: 27232185 DOI: 10.1371/journal.pone.0156177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
204 Hamada Y, Getahun H, Tadesse BT, Ford N. HIV-associated tuberculosis. Int J STD AIDS 2021;32:780-90. [PMID: 33612015 DOI: 10.1177/0956462421992257] [Reference Citation Analysis]
205 Quinn CM, Poplin V, Kasibante J, Yuquimpo K, Gakuru J, Cresswell FV, Bahr NC. Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum of Disease. Life (Basel) 2020;10:E262. [PMID: 33138069 DOI: 10.3390/life10110262] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
206 Meriki HD, Tufon KA, Atanga PN, Ane-Anyangwe IN, Anong DN, Cho-Ngwa F, Nkuo-Akenji T. Drug resistance profiles of Mycobacterium tuberculosis complex and factors associated with drug resistance in the Northwest and Southwest Regions of Cameroon. PLoS One 2013;8:e77410. [PMID: 24146991 DOI: 10.1371/journal.pone.0077410] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]